ImmunityBio, Inc. Common Stock
IBRX
$8.05
-4.17%
ImmunityBio, Inc. is a biotechnology company focused on developing and commercializing next-generation immunotherapies designed to activate the patient's immune system to fight cancer and infectious diseases. Its lead product, ANKTIVA, is an IL-15 superagonist approved for bladder cancer, and the company is building a broader pipeline including vaccines and NK-cell therapies. As a niche player in the immuno-oncology space, ImmunityBio differentiates itself through its Cancer BioShield platform, which harnesses both innate and adaptive immunity. The current investor narrative centers on regulatory momentum—FDA acceptance of an expanded bladder cancer filing, EU approval, and a Japanese partnership—while the stock remains highly volatile and speculative, with a short interest ratio near 15 days to cover.…
IBRX
ImmunityBio, Inc. Common Stock
$8.05
Related headlines
Investment Opinion: Should I buy IBRX Today?
Rating: Buy. The thesis is that ImmunityBio's regulatory momentum and explosive revenue growth (406.9% YoY) will drive ANKTIVA's commercial success, leading to significant upside despite current losses. Analyst consensus is Buy with an average target of $12.75, implying 58.4% upside from $8.05. Supporting evidence includes: trailing PS of 16.1x (premium to industry 3.5x) but forward PS of 0.7x if revenue estimates are met; gross margin of 99.3%; revenue growth from $7.55M to $38.3M in Q4; and a 1-year price change of +245.5%. Risks include cash burn, negative equity, and speculative valuation. This Buy would downgrade to Hold if revenue growth decelerates below 100% YoY or if the company announces a dilutive offering, and to Sell if regulatory setbacks occur. Overall, the stock is overvalued on trailing metrics but potentially undervalued on forward estimates, making it a high-risk, high-reward opportunity.
Sign up to view all
IBRX 12-Month Price Forecast
The AI assessment leans bullish due to the strong revenue growth and regulatory momentum, which are tangible and data-backed. However, confidence is medium because of the extreme cash burn and negative equity, which could derail the thesis. The key factors support a positive outlook if execution continues, but the high short interest and speculative valuation warrant caution. An upgrade to high confidence would require sustained revenue growth above 100% YoY and a path to profitability, while a downgrade would occur if revenue growth decelerates sharply or the company announces a major dilutive offering.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on ImmunityBio, Inc. Common Stock's 12-month outlook, with a consensus price target around $12.75 and implied upside of +58.4% versus the current price.
Average Target
$12.75
0 analysts
Implied Upside
+58.4%
vs. current price
Analyst Count
—
covering this stock
Price Range
$12 - $15
Analyst target range
Only 4 analysts cover ImmunityBio, with a consensus recommendation of 'Buy' (though the data shows 'none' for the recommendation field, the ratings from D. Boral Capital, Piper Sandler, and HC Wainwright are all Buy/Overweight). The average target price is $12.75, implying 58.4% upside from the current price of $8.05. The target range is $12.00 to $15.00, with the low target still 49% above the current price, indicating strong bullish sentiment among the few analysts covering the stock. The high target of $15.00 assumes successful expansion of ANKTIVA into new indications and geographies, while the low target of $12.00 still prices in significant commercial success. The narrow spread between low and high targets (25%) suggests relatively high conviction, but the limited coverage (4 analysts) means the stock may be under-researched, leading to higher volatility and less efficient price discovery. Recent ratings have been consistently positive, with no downgrades, and the institutional ratings show repeated Buy affirmations from D. Boral Capital and HC Wainwright, reinforcing the bullish outlook.
Bulls vs Bears: IBRX Investment Factors
ImmunityBio presents a classic high-risk, high-reward biotech investment. The bull case is anchored by explosive revenue growth (406.9% YoY), regulatory wins (FDA acceptance, EU approval), and unanimous analyst Buy ratings with 58.4% upside. The bear case is equally compelling, with deep losses, negative equity, massive cash burn, and a speculative valuation that prices in extraordinary growth. Currently, the bull side has stronger evidence given the tangible commercial progress and regulatory momentum, but the single most important tension is whether ANKTIVA's revenue ramp can accelerate enough to justify the valuation and offset the relentless cash burn. If revenue growth decelerates or regulatory setbacks occur, the stock could face severe downside, given its high short interest and fragile balance sheet.
Bullish
- Explosive Revenue Growth: Q4 2025 revenue surged 406.9% YoY to $38.3 million, driven by ANKTIVA's commercial launch. This rapid scaling from a negligible base demonstrates strong early market adoption and validates the drug's commercial potential.
- Regulatory Momentum: FDA accepted expanded bladder cancer filing, EU approval secured, and Japanese partnership established. These milestones expand ANKTIVA's addressable market and de-risk the commercial trajectory, supporting the bullish analyst targets.
- High Gross Margins: Gross margin is 99.3% (TTM), typical for a proprietary biologic. This exceptional profitability on each dollar of revenue provides a strong foundation for future operating leverage as sales scale.
- Analyst Consensus Buy: All 4 covering analysts rate IBRX a Buy, with an average target of $12.75, implying 58.4% upside. The low target of $12.00 is still 49% above the current price, indicating high conviction even in the bearish scenario.
Bearish
- Deep Unprofitability: Net loss of $61.9 million in Q4 2025, though narrowed from $129.6 million in Q1 2025. Operating margin is -226.0% (TTM), reflecting heavy R&D and commercialization spending that will pressure cash flow for the foreseeable future.
- Negative Shareholder Equity: Debt-to-equity ratio is -1.76, indicating negative equity. This financial fragility raises solvency concerns and limits the company's ability to withstand prolonged losses without additional dilutive financing.
- Massive Cash Burn: Free cash flow is -$308.0 million (TTM), requiring constant external financing. The company raised $53.7 million in Q4 2025 alone, and continued dilution will likely pressure the stock price.
- Speculative Valuation: Trailing PS ratio of 16.1x is 360% above the industry average of 3.5x. The forward PS of 0.7x implies the market expects explosive revenue growth, which is highly speculative and vulnerable to disappointment.
IBRX Technical Analysis
ImmunityBio has exhibited a dramatic recovery over the past year, with a 1-year price change of +245.5%, though the stock remains well below its 52-week high of $12.43. Currently trading at $8.05, the stock sits at 64.7% of its 52-week range (calculated as (8.05-1.95)/(12.43-1.95)), indicating it has recovered significantly from its lows but is still 35% off its peak. This positioning suggests a strong uptrend that has lost some momentum, as the stock is neither at extreme highs nor lows, but the 52-week low of $1.95 highlights the extreme volatility and risk inherent in this name.
Beta
0.13
0.13x market volatility
Max Drawdown
-42.3%
Largest decline past year
52-Week Range
$2-$12
Price range past year
Annual Return
+245.5%
Cumulative gain past year
| Period | IBRX Return | S&P 500 |
|---|---|---|
| 1m | +17.9% | +3.0% |
| 3m | +7.0% | +1.4% |
| 6m | -17.7% | +13.1% |
| 1y | +245.5% | +19.3% |
| ytd | +298.5% | +12.8% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
IBRX Fundamental Analysis
Revenue has grown rapidly from a negligible base, with Q4 2025 revenue of $38.3 million, up 406.9% year-over-year (from $7.55 million in Q4 2024). This growth is driven by ANKTIVA sales, which are scaling as the drug gains approvals and launches in new markets. However, the company remains deeply unprofitable, with a net loss of $61.9 million in Q4 2025, though the net loss has narrowed from $129.6 million in Q1 2025. Gross margins are exceptionally high at 99.3% (TTM), typical for a biotech with a proprietary drug, but operating margins are deeply negative at -226.0% (TTM), reflecting heavy R&D and commercialization spending. The company's balance sheet shows a current ratio of 5.1, indicating strong short-term liquidity, but a negative debt-to-equity ratio of -1.76 suggests negative shareholder equity, a red flag for financial stability. Free cash flow is deeply negative at -$308.0 million (TTM), and the company relies on external financing, having raised $53.7 million in common stock in Q4 2025 alone. ROE is 70.3%, but this is distorted by negative equity, and the company's cash burn rate remains a key risk.
Quarterly Revenue
$38285000.0B
2025-12
Revenue YoY Growth
+406.9%
YoY Comparison
Gross Margin
88.9%
Latest Quarter
Free Cash Flow
$-308007000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is IBRX Overvalued?
Given the company's negative net income and EBITDA, the price-to-sales (PS) ratio is the most appropriate valuation metric. The trailing PS ratio is 16.1x, while the forward PS ratio (based on estimated revenue of $2.55 billion) is approximately 0.7x, implying the market expects explosive revenue growth. This wide gap suggests the market is pricing in a massive revenue ramp, which is highly speculative. Compared to the industry average PS ratio of 3.5x (from valuation data), ImmunityBio trades at a 360% premium on trailing sales, reflecting its early-stage commercial launch and high growth potential. However, the forward PS of 0.7x would be a significant discount if the revenue estimates are met, indicating the market is pricing in a dramatic inflection. Historically, the PS ratio has ranged from 51.2x (Q4 2025) to 89,486x (Q1 2024), and the current 16.1x is near the lower end of that range, suggesting the stock is relatively less expensive than its own history, though still expensive in absolute terms.
PE
-5.2x
Latest Quarter
vs. Historical
N/A
5-Year PE Range 17x~59x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
-11.7x
Enterprise Value Multiple
Investment Risk Disclosure
Financial risks are severe. The company is deeply unprofitable with a net loss of $61.9 million in Q4 2025 and negative operating margin of -226.0% (TTM). Free cash flow is -$308.0 million (TTM), requiring constant external financing; the company raised $53.7 million in Q4 2025 alone. Negative shareholder equity (debt-to-equity -1.76) and a current ratio of 5.1 provide some liquidity, but the cash burn rate is unsustainable without continued dilution or debt, which could pressure the stock price and signal financial instability.
FAQ
The key risks are: 1) Financial risk: deep losses and negative equity (debt-to-equity -1.76) could lead to bankruptcy if cash runs out; 2) Market risk: high short interest (14.88 days to cover) and speculative valuation (PS 16.1x) make the stock prone to sharp declines; 3) Regulatory risk: FDA or EU decisions could delay or block ANKTIVA's expansion; 4) Competitive risk: other bladder cancer therapies could erode market share. The most severe risk is a cash crunch forcing dilutive financing, which could drop the stock to the 52-week low of $1.95, a -76% decline from current levels.
The 12-month forecast is bullish, with a base case target of $10.00-$12.75 (50% probability), a bull case of $12.00-$15.00 (30% probability), and a bear case of $1.95-$7.00 (20% probability). The most likely scenario is the base case, where revenue growth continues but the company remains unprofitable, leading to a stock price near the analyst average of $12.75. The key assumption is that ANKTIVA sales ramp as expected, with no major regulatory or clinical setbacks. Investors should monitor quarterly revenue growth and cash burn to gauge which scenario is unfolding.
On trailing metrics, IBRX is overvalued with a PS ratio of 16.1x, a 360% premium to the industry average of 3.5x. However, on forward estimates, the PS ratio is 0.7x, implying the market expects explosive revenue growth. This wide gap suggests the stock is priced for perfection, and any disappointment could lead to a sharp de-rating. Historically, the PS ratio has ranged from 51.2x to 89,486x, so the current 16.1x is relatively low, but still expensive in absolute terms. The valuation implies the market expects revenue to grow to $2.55 billion, which is a high bar.
IBRX offers a compelling risk/reward for speculative investors, with analyst targets implying 58.4% upside and a consensus Buy rating. However, the stock is highly volatile, with a 52-week range of $1.95 to $12.43, and carries significant risks including deep losses and negative equity. It is a good buy for those who believe in ANKTIVA's commercial potential and can tolerate potential drawdowns of 40% or more. For conservative investors, the risks outweigh the rewards, and it is better to wait for evidence of sustained profitability or a more stable balance sheet.
IBRX is more suitable for long-term investment (3-5 years) given its early-stage commercial launch and high volatility (beta 0.125, but price swings are extreme). The stock has a 1-year change of +245.5%, but also a max drawdown of -42.34%, making it risky for short-term trading. Long-term investors can ride out volatility and benefit from ANKTIVA's potential market expansion. However, the company's cash burn and negative equity mean that long-term survival is not guaranteed, so investors must be prepared for the possibility of total loss. A minimum holding period of 3 years is recommended to allow the commercial story to develop.